Shares of SKB BIO (06990) have risen more than 6%. At the time of writing, the stock is up 5.33% to HK$419.4, with a turnover of HK$29.2642 million.

The recent surge is linked to the company's presentation at the 2026 ASCO conference. SKB BIO delivered an oral report on the Phase III OptiTROP-Lung05 study results for its sac-TMT therapy combined with a PD-1 inhibitor as a first-line treatment for NSCLC patients with PD-L1 TPS ≥1%.

Initial Analysis

Analysis suggests the company's core product, sac-TMT, is progressing smoothly through global clinical trials, consistently demonstrating its potential to be best-in-class globally. The product is on the verge of entering the commercialization phase overseas, with its partnership with Merck poised to unlock significant market potential in international markets.

Further Clinical Developments

It was noted that Merck previously announced that the global pivotal Phase 3 TroFuse-005 study for sac-TMT monotherapy in third-line or later treatment of endometrial cancer patients met its primary endpoints for overall survival and progression-free survival. This makes sac-TMT the first and only ADC to achieve this goal in this specific treatment setting for endometrial cancer patients.

Merck has initiated 17 registration-focused clinical trials for sac-TMT. It is anticipated that more global Phase 3 data will be released successively in the future, continually validating the product's potential in the global market.